- Wikimedia Commons
SAN FRANCISCO – A woman in Nevada died in September from an infection that resisted every kind of antibiotic we have in the US that could have cured it.
The case, which the Centers for Disease Control and Prevention reported Thursday, is part of the growing problem of antibiotic resistance, which is expected to kill 10 million people annually by 2050.
“I think it’s concerning,” Alexander Kallen, a medical officer at the CDC’s division of healthcare quality promotion, told Stat News. “We have relied for so long on just newer and newer antibiotics. But obviously the bugs can often [develop resistance] faster than we can make new ones.”
That’s in part because it takes a long time to develop antibiotics, and even those that have made it through development face stumbling blocks. As a result, many major pharmaceutical companies have stopped developing new antibiotics altogether.
Last year, for example, the Food and Drug Administration turned down Cempra Pharmaceuticals‘ new antibiotic, a drug called solithromycin, which was designed to fight a type of bacterial pneumonia. The FDA cited, in part, too little information on how the drug might affect the liver. It recommended an additional trial that would require testing the antibiotic on 9,000 people, according to Cempra.
Why it’s so hard to get new antibiotics approved
Despite these roadblocks, the biotech company Paratek Pharmaceuticals is currently working on a new antibiotic called omadacycline. So far, the approval process for the drug has taken roughly two decades.
The drug would treat skin infections, pneumonia, and urinary tract infections. The company expects results by July from phase-three trials looking at skin infections and pneumonia.
“After 21 years of investment … we will have the pivotal data,” Paratek President Evan Loh told Business Insider at the JPMorgan Healthcare Conference on Thursday. If the drug gets on the market, it will have been 15 years since it went into human trials, he said.
So why does it take so long? Part of the problem is just tricky science – sorting through different compounds to figure out which antibiotic might work can take time. But it also has a lot to do with the companies running the trials staying afloat financially, Loh said.
And at that point, sometimes legislation can come in handy. Loh said the GAIN Act helped Paratek “save the company” by extending its patents on its antibiotics by five years. The act, which passed in 2012, aimed to incentivize companies to develop antibiotics by giving them extra time under patent protection to make money before facing generic competition.
If approved, Paratek’s new drug will be added to the arsenal of medicines designed to take on resistant bacteria, which will be key as more deaths are attributed to antibiotic-resistant bacteria.
“In the pre-antibiotic era, people were dead by the time they were 30 because of infections,” Adam Woodrow, Paratek’s chief commercial officer, told Business Insider. “Can you ever imagine that scenario where we get back to that situation?
“There was once this time where we were keeping up. Now we’ve sort of fallen behind,” said Woodrow. “And the group of antibiotics that should be there to combat these pathogens have just disappeared.”